Immunovant (IMVT) Cash from Operations (2019 - 2026)
Immunovant's (IMVT) quarterly Cash from Operations came in at 95059000.0 in Q1 2026, up 14.08% YoY from 83326407.98 in Q1 2025, and down 2.96% on a QoQ basis from 92325000.0 in Q4 2025.
Powered by 
Analysis
Immunovant (IMVT) Cash from Operations (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Cash from Operations data on file, last reported at 95059000.0 in Q1 2026.
- Quarterly Cash from Operations rose 14.08% year-over-year to 95059000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 407310000.0 (down 8.36% YoY) and the FY2026 annual result came in at 407310000.0, down 8.36% from the prior year.
- Cash from Operations retreated to 95059000.0 in Q1 2026, from 92325000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 20186000.0 in Q3 2022 to a low of 117411000.0 in Q2 2025.
- A 5-year average of 71680000.0 and a median of 65819000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 210.26% — and 2023, when it increased 28.03%.
- Tracing IMVT's Cash from Operations over 5 years: stood at 46395000.0 in 2022, then retreated by 1.52% to 47098000.0 in 2023, then sank by 113.15% to 100391000.0 in 2024, then climbed by 8.03% to 92325000.0 in 2025, then declined by 2.96% to 95059000.0 in 2026.
- The last three Cash from Operations figures came in at 95059000.0 (Q1 2026), 92325000.0 (Q4 2025), and 102515000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Immunovant | 8.07 Bn | 8.07 Bn | - | -124.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -124.41 Mn |
| Mar 31, 2026 | -95.06 Mn |
| Dec 31, 2025 | -92.33 Mn |
| Sep 30, 2025 | -102.52 Mn |
| Jun 30, 2025 | -117.41 Mn |
| Mar 31, 2025 | -110.64 Mn |
| Dec 31, 2024 | -100.39 Mn |
| Sep 30, 2024 | -88.65 Mn |
| Jun 30, 2024 | -76.20 Mn |
| Mar 31, 2024 | -59.70 Mn |
| Dec 31, 2023 | -47.10 Mn |
| Sep 30, 2023 | -60.06 Mn |
| Jun 30, 2023 | -47.37 Mn |
| Mar 31, 2023 | -55.79 Mn |
| Dec 31, 2022 | -46.40 Mn |
| Sep 30, 2022 | -20.19 Mn |
| Jun 30, 2022 | -65.82 Mn |
| Mar 31, 2022 | -32.96 Mn |
| Dec 31, 2021 | -31.90 Mn |
| Sep 30, 2021 | -20.05 Mn |